Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline BRCA1/2 Mutation Carriers: A Retrospective Cohort Study
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose: This study investigated the uptake rate of risk-reducing salpingo-oophorectomy (RRSO) and surgical outcomes of germline BRCA1/2 mutation carriers at Seoul National University Hospital (SNUH). Materials and Methods: We examined the records of 824 women who underwent germline BRCA1/2 gene testing at SNUH between 2005 and 2020. Among them, we identified women with a pathogenic mutation on either the BRCA1 or the BRCA2 gene, and excluded ovarian cancer patients. Characteristics of participants who underwent RRSO (RRSO group) were compared to those who did not (non-RRSO group). Surgical outcomes and pathologic results were investigated in the RRSO group. Results: There were 117 BRCA1/2 mutation carriers included in the analysis. The uptake rate of RRSO was 70.1% (82/117). Older age (mean: 48.8 years vs. 42.1 years; p=0.002) and higher employment rate (65.9% vs. 14.3%; p<0.001) were observed in the RRSO group compared to the non-RRSO group. However, no differences in other factors, such as personal and family history of breast cancer, were observed between the two groups. In the RRSO group, the median time interval between the genetic test and RRSO was 10.0 months, and there were three (3.7%) incidental cases of high-grade serous carcinoma. However, one patient in the non-RRSO group developed primary peritoneal cancer after 103.8 months of surveillance. Conclusion: The uptake rate of RRSO in BRCA1/2 mutation carriers was about 70%. Considering incidental cancer cases in women without abnormal findings on preoperative evaluation, BRCA1/2-mutated women might refrain from the delayed implementation of RRSO after the genetic test.
Abstract
Purpose: This study investigated the uptake rate of risk-reducing salpingo-oophorectomy (RRSO) and surgical outcomes of germline BRCA1/2 mutation carriers at Seoul National University Hospital (SNUH). Materials and Methods: We examined the records of 824 women who underwent germline BRCA1/2 gene testing at SNUH between 2005 and 2020. Among them, we identified women with a pathogenic mutation on either the BRCA1 or the BRCA2 gene, and excluded ovarian cancer patients. Characteristics of participants who underwent RRSO (RRSO group) were compared to those who did not (non-RRSO group). Surgical outcomes and pathologic results were investigated in the RRSO group. Results: There were 117 BRCA1/2 mutation carriers included in the analysis. The uptake rate of RRSO was 70.1% (82/117). Older age (mean: 48.8 years vs. 42.1 years; p=0.002) and higher employment rate (65.9% vs. 14.3%; p<0.001) were observed in the RRSO group compared to the non-RRSO group. However, no differences in other factors, such as personal and family history of breast cancer, were observed between the two groups. In the RRSO group, the median time interval between the genetic test and RRSO was 10.0 months, and there were three (3.7%) incidental cases of high-grade serous carcinoma. However, one patient in the non-RRSO group developed primary peritoneal cancer after 103.8 months of surveillance. Conclusion: The uptake rate of RRSO in BRCA1/2 mutation carriers was about 70%. Considering incidental cancer cases in women without abnormal findings on preoperative evaluation, BRCA1/2-mutated women might refrain from the delayed implementation of RRSO after the genetic test.
참고문헌 (24)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Committee on Practice Bulletins–Gynecology, "Practice Bulletin No 182 : hereditary breast and ovarian cancer syndrome", Obstet Gynecol, 130, pp.e110~e126 (2017)
- Menon U, "Ovarian cancer prevention and screening", Obstet Gynecol, 131, pp.909~927 (2018)
- Antoniou A, "Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history : a combined analysis of 22 studies", Am J Hum Genet, 72, pp.1117~1130 (2003)
- Daly MB, "NCCN guidelines insights: genetic", familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020: featured updates to the NCCN guidelines, 2020, pp.18, 380~391
- Kim SI, "Effect of BRCA mutational status on survival outcome in advancedstage high-grade serous ovarian cancer", J Ovarian Res, 12, pp.40~ (2019)
- 최민철, "Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO)", Journal of Gynecologic Oncology, 27(4), pp.1~4 (2016), 대한부인종양학회
- Gordhandas S, "Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits", Gynecol Oncol, 153, pp.192~200 (2019)
- Miller SM, "New strategies in ovarian cancer : uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy", Clin Cancer Res, 16, pp.5094~5106 (2010)
- Bradbury AR, "Uptake and timing of bilateral prophylactic salpingooophorectomy among BRCA1 and BRCA2 mutation carriers", Genet Med, 10, pp.161~166 (2008)
- Metcalfe KA, "Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation", Clin Genet, 73, pp.474~479 (2008)
- Kim SI, "Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers : experience at the National Cancer Center of Korea", J Cancer Res Clin Oncol, 142, pp.333~340 (2016)
- Sidon L, "Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation : evidence for lower uptake in women affected by breast cancer and older women", Br J Cancer, 106, pp.775~779 (2012)
- Chai X, "Use of risk-reducing surgeries in a prospective cohort of 1, 499BRCA1 and BRCA2 mutation carriers", Breast Cancer Res Treat, 148, pp.397~406 (2014)
- Piedimonte S, "Occult tubal carcinoma after risk-reducing salpingo-oophorectomy : a systematic review", Obstet Gynecol, 135, pp.498~508 (2020)
- Palaiologos K, "Prophylactic bilateral salpingo-oophorectomy in BRCA2 mutation with incidental finding of serous tubal intraepithelial carcinoma (STIC) and subsequent diagnosis of primary peritoneal carcinoma (PPC): a case report and review of current literature", Cureus, 12, pp.e9301~ (2020)
- Colgan TJ, "Occult carcinoma in prophylactic oophorectomy specimens : prevalence and association with BRCA germline mutation status", Am J Surg Pathol, 25, pp.1283~1289 (2001)
- Agoff SN, "Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations", Am J Surg Pathol, 28, pp.1112~1114 (2004)
- Vaughan MH, "Serous tubal intraepithelial carcinoma : an incidental finding at the time of prophylactic bilateral salpingo-oophorectomy", Case Rep Obstet Gynecol, 2015, pp.760429~ (2015)
- Mavaddat N, "Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk : an international prospective cohort of BRCA1 and BRCA2 mutation carriers", Breast Cancer Res, 22, pp.8~ (2020)
- Gaba F, "Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention : a cohort study", BJOG, 128, pp.714~726 (2021)
- Ghezelayagh TS, "Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention", Fam Cancer, 19, pp.143~151 (2020)
- Nebgen DR, "Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction : a pilot study in women with BRCA1", 2 mutations, 2018, pp.150, 79~84
- Gaba F, "Risk-reducing early salpingectomy and delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in women at increased risk : a commentary", BJOG, 126, pp.831~839 (2019)